Loading...
XNAS
CAMP
Market cap92mUSD
Jul 09, Last price  
4.34USD
1D
3.58%
1Q
-3.34%
IPO
-55.49%
Name

CAMP4 Therapeutics Corp

Chart & Performance

D1W1MN
XNAS:CAMP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-2.45%
Rev. gr., 5y
-59.18%
Revenues
3m
+436.50%
222,339,000140,907,00098,370,000112,113,000114,333,000138,728,000180,579,000235,903,000250,606,000280,719,000351,102,000365,912,000363,800,000366,107,000308,587,000295,839,0000350,000652,0003,498,000
Net income
-80m
L+55.25%
-31,188,000-84,149,000-49,665,000-10,851,000-3,283,0005,218,00044,626,00011,803,00016,508,00016,940,000-7,151,00016,617,00018,398,000-78,774,000-21,157,000-31,148,000-44,192,000-49,291,000-51,791,000-80,403,000
CFO
-30m
L-35.14%
16,723,000-1,476,00013,760,0002,472,000857,00012,432,00016,597,00022,816,00028,645,00047,400,00025,796,00066,894,00047,740,00011,544,00028,585,000-4,218,000-38,543,000-44,155,000-45,562,000-29,553,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
URL
https://www.camp4tx.com/
IPO date
Oct 11, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑112023‑022022‑022021‑022020‑022019‑022018‑022017‑02
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT